Q2 EPS Estimates for Addus HomeCare Cut by William Blair

Addus HomeCare Co. (NASDAQ:ADUS) – Equities research analysts at William Blair cut their Q2 2025 earnings per share estimates for shares of Addus HomeCare in a report released on Tuesday, May 13th. William Blair analyst J. Haase now anticipates that the company will post earnings per share of $1.32 for the quarter, down from their prior estimate of $1.44. The consensus estimate for Addus HomeCare’s current full-year earnings is $4.59 per share. William Blair also issued estimates for Addus HomeCare’s Q3 2025 earnings at $1.41 EPS, Q4 2025 earnings at $1.60 EPS, FY2025 earnings at $5.60 EPS and FY2026 earnings at $6.12 EPS.

Addus HomeCare (NASDAQ:ADUS) last issued its quarterly earnings data on Monday, May 5th. The company reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.33 by $0.09. The firm had revenue of $337.71 million during the quarter, compared to analyst estimates of $341.66 million. Addus HomeCare had a return on equity of 9.62% and a net margin of 6.50%. The business’s quarterly revenue was up 20.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.21 earnings per share.

ADUS has been the subject of several other research reports. StockNews.com lowered Addus HomeCare from a “buy” rating to a “hold” rating in a research report on Wednesday, February 26th. Oppenheimer lifted their price target on Addus HomeCare from $145.00 to $150.00 and gave the stock an “outperform” rating in a research report on Friday, January 24th. Stephens reiterated an “overweight” rating and issued a $142.00 price target on shares of Addus HomeCare in a research report on Wednesday, March 12th. Macquarie lifted their price target on Addus HomeCare from $129.00 to $133.00 and gave the stock an “outperform” rating in a research report on Thursday, May 8th. Finally, JMP Securities restated a “market outperform” rating and set a $150.00 target price on shares of Addus HomeCare in a research report on Tuesday, April 22nd. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $142.57.

Addus HomeCare Trading Up 1.6%

ADUS opened at $111.63 on Friday. The firm has a market cap of $2.05 billion, a P/E ratio of 25.54, a P/E/G ratio of 1.41 and a beta of 0.85. Addus HomeCare has a 12 month low of $88.96 and a 12 month high of $136.72. The stock has a 50-day moving average of $100.30 and a 200 day moving average of $113.82.

Hedge Funds Weigh In On Addus HomeCare

A number of large investors have recently made changes to their positions in ADUS. Natixis boosted its holdings in Addus HomeCare by 111.9% in the fourth quarter. Natixis now owns 250 shares of the company’s stock valued at $31,000 after purchasing an additional 132 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in Addus HomeCare by 324.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 280 shares of the company’s stock valued at $35,000 after buying an additional 214 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new position in Addus HomeCare in the 1st quarter valued at about $41,000. Parkside Financial Bank & Trust lifted its stake in Addus HomeCare by 38.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 531 shares of the company’s stock worth $67,000 after purchasing an additional 148 shares in the last quarter. Finally, Meeder Asset Management Inc. purchased a new position in Addus HomeCare in the 4th quarter worth approximately $77,000. 95.35% of the stock is owned by institutional investors and hedge funds.

Addus HomeCare Company Profile

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health.